Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares soaring over 37% in early trading after a $1.27 billion IPO. The offering was priced at HK$44.05—at the top of its range—reflecting strong investor appetite for the Chinese biopharmaceutical giant.
Shares opened at HK$57.10, marking a 29.6% jump from the offer price, and peaked at HK$60.20 shortly after the market opened. The robust debut highlights renewed investor confidence in Hong Kong’s IPO market, which has seen a notable resurgence, particularly from mainland Chinese companies pursuing dual listings.
Hengrui, already publicly traded in Shanghai, is one of China’s top drugmakers, specializing in oncology, innovative therapies, and biosimilars. The company plans to allocate IPO proceeds to accelerate clinical trials, scale production capabilities, and support global expansion. The strategic move is aimed at strengthening its international footprint and enhancing its competitiveness in the global pharmaceutical industry.
The timing of Hengrui’s successful listing coincides with the broader uptick in Hong Kong’s capital markets. Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) also debuted strongly, underscoring heightened interest in high-growth Chinese firms across sectors.
Jiangsu Hengrui’s performance signals positive momentum for biotech and pharmaceutical IPOs in Asia, particularly as global investors look toward companies with robust pipelines and innovation-driven strategies. With a clear focus on global growth and R&D, Hengrui's dual listing positions it to attract more institutional interest while reinforcing Hong Kong’s status as a hub for health tech and biotech capital.
